Hypomyelinating Leukodystrophy 7

Mendelian MONDO:0011897 Pathograph 8 Show in embeddings browser POLR3-related leukodystrophy

Hypomyelinating leukodystrophy 7 (HLD7) is an autosomal recessive hypomyelinating leukodystrophy caused by biallelic pathogenic variants in POLR3A, the gene encoding the largest, catalytic subunit of RNA polymerase III (Pol III). It lies within the POLR3-related leukodystrophy / "4H leukodystrophy" spectrum (hypomyelination, hypodontia, hypogonadotropic hypogonadism). Clinically it features progressive neurologic dysfunction predominated by cerebellar and motor signs (ataxia, spasticity, tremor, dystonia, dysarthria) with cognitive decline, plus extra-neurologic dental, endocrine, and ocular involvement and a characteristic diffuse-hypomyelination MRI pattern with relative preservation of early-myelinating structures.

Ask OpenScientist

Ask a research question about Hypomyelinating Leukodystrophy 7. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

4
Pathophys.
13
Phenotypes
8
Pathograph
1
Genes
2
Medical Actions
2
Subtypes
10
References
1
Deep Research
◆

Subtypes

2
POLR3A-related HLD7
The canonical HLD7 subtype caused by biallelic pathogenic variants in POLR3A. POLR3A-associated disease tends to follow a more severe clinical course than POLR3B-related 4H leukodystrophy.
Show evidence (2 references)
PMID:38561452 SUPPORT Human Clinical
"This study aims to analyze the clinical phenotype and genetic function of a family with HLD-7 caused by POLR3A mutation."
Defines HLD7 as the POLR3A-caused hypomyelinating leukodystrophy subtype.
PMID:25339210 SUPPORT Human Clinical
"Mutations in POLR3A are associated with a more severe clinical course."
Supports POLR3A-related disease as the more severe end of the 4H/POLR3-related leukodystrophy spectrum.
POLR3B-related 4H leukodystrophy
A clinically overlapping POLR3-related leukodystrophy subtype caused by biallelic POLR3B variants, generally following a milder disease course than POLR3A-related disease; homozygosity for the common c.1568T>A POLR3B allele causes a mild phenotype.
Show evidence (2 references)
PMID:25339210 SUPPORT Human Clinical
"The disease course was milder in patients with POLR3B than in patients with POLR3A mutations."
Distinguishes POLR3B-related 4H leukodystrophy as the milder subtype within the spectrum.
PMID:25339210 SUPPORT Human Clinical
"Most patients carried the common c.1568T>A POLR3B mutation on one allele, homozygosity for which causes a mild phenotype."
Documents the recurrent POLR3B c.1568T>A allele associated with a mild phenotype when homozygous.
⚙

Pathophysiology

4
Biallelic POLR3A Loss of Function
Biallelic pathogenic variants in POLR3A (the largest, catalytic subunit of RNA polymerase III) impair Pol III, the enzyme that transcribes many small non-coding RNAs including tRNAs and 5S rRNA. This is the proximal molecular lesion of HLD7.
transcription by RNA polymerase III GO:0006383 ↓ DECREASED
Downstream
Impaired Pol III Transcript Output Defective Pol III lowers production of its small non-coding RNA transcripts (tRNAs, 5S rRNA).
Show evidence (2 references)
PMID:38561452 SUPPORT In Vitro
"overexpression of wild-type POLR3A protein significantly enhanced Pol III transcription of 5S rRNA and tRNA Leu-CAA."
Establishes POLR3A as a determinant of Pol III transcription, the activity impaired by HLD7 variants.
PMID:36140376 SUPPORT Human Clinical
"Recessive mutations in the POLR3A gene cause POLR3-HLD (the second-most-common form of childhood-onset hypomyelinating leukodystrophy), a neurodegenerative disorder featuring deficient cerebral myelin formation."
Supports recessive POLR3A variants as the cause of POLR3-HLD with deficient myelin formation.
Impaired Pol III Transcript Output
The mutant POLR3A protein fails to support normal Pol III activity, reducing Pol III transcript outputs (e.g., tRNA Leu-CAA, BC200) and downstream readouts of myelin biology, linking transcriptional dysfunction to reduced myelin basic protein expression.
tRNA transcription by RNA polymerase III GO:0042797 ↓ DECREASED
Downstream
Oligodendrocyte and Myelin Dysfunction Reduced Pol III transcript supply perturbs oligodendrocyte translation and myelin production.
Show evidence (2 references)
PMID:38561452 SUPPORT In Vitro
"Pol III transcription function was frustrated (POLR3A, BC200, and tRNA Leu-CAA expression decreased), and MBP and 18S rRNA expressions were decreased."
Directly links the POLR3A p.Cys767Phe variant to reduced Pol III transcripts and decreased myelin basic protein expression.
PMID:37915380 SUPPORT In Vitro
"Pol III transcription was also shown to be aberrant, with a significant decrease in 7SK RNA and several distinct tRNA genes"
Supports reduced Pol III tRNA output as a shared mechanism across POLR3-related leukodystrophies.
Oligodendrocyte and Myelin Dysfunction
Reduced Pol III transcript supply is hypothesized to impair oligodendrocyte differentiation and the high translational demand of myelin protein synthesis, yielding deficient central nervous system myelination.
oligodendrocyte CL:0000128
oligodendrocyte differentiation GO:0048709 ⚠ ABNORMAL central nervous system myelination GO:0022010 ↓ DECREASED
Downstream
Central Nervous System Hypomyelination Oligodendrocyte and myelin dysfunction manifests as diffuse CNS hypomyelination.
Show evidence (2 references)
PMID:36140376 SUPPORT Human Clinical
"a neurodegenerative disorder featuring deficient cerebral myelin formation."
Supports deficient cerebral myelin formation as the cellular/tissue-level consequence in POLR3-HLD.
PMID:37755363 SUPPORT Other
"An increasing number of studies have reported genetic mutations that cause protein misfolding, protein dysfunction, and/or mislocalization associated with HLD."
Supports protein dysfunction as the mechanistic theme underlying hypomyelinating leukodystrophies including POLR3-related disease.
Central Nervous System Hypomyelination
Diffuse hypomyelination of central nervous system white matter, with relative preservation of early-myelinating structures, is the defining tissue-level output and produces the characteristic brain MRI pattern of POLR3-related leukodystrophy.
myelination GO:0042552 ↓ DECREASED
Show evidence (2 references)
PMID:25339210 SUPPORT Human Clinical
"the combination of hypomyelination with relative T2 hypointensity of the ventrolateral thalamus, optic radiation, globus pallidus, and dentate nucleus, cerebellar atrophy, and thinning of the corpus callosum suggests the diagnosis."
Describes the diffuse hypomyelination pattern that defines the disease at the tissue/imaging level.
PMID:37915380 SUPPORT Human Clinical
"Her MRI was notable for diffuse hypomyelination with myelin preservation of early myelinating structures, characteristic of POLR3-related leukodystrophy."
Supports diffuse hypomyelination with preservation of early-myelinating structures as characteristic of POLR3-related leukodystrophy.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Hypomyelinating Leukodystrophy 7 Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

13
Endocrine 1
Hypogonadotropic Hypogonadism Hypogonadotropic hypogonadism HP:0000044
Show evidence (1 reference)
PMID:22855961 SUPPORT Human Clinical
"more commonly, hypogonadotropic hypogonadism manifesting as delayed, arrested, or absent puberty."
GeneReviews documents hypogonadotropic hypogonadism as the common endocrine manifestation.
Eye 1
Myopia VERY_FREQUENT Myopia HP:0000545
Show evidence (1 reference)
PMID:25339210 SUPPORT Human Clinical
"Other than the typical neurologic, dental, and endocrine features, myopia was seen in almost all and short stature in 50%."
Reports myopia in almost all patients, supporting the VERY_FREQUENT band.
Head and Neck 2
Oligodontia Oligodontia HP:0000677
Show evidence (1 reference)
PMID:22855961 SUPPORT Human Clinical
"Abnormal dentition (delayed dentition, hypodontia, oligodontia, and abnormally placed or shaped teeth)."
GeneReviews lists oligodontia among the cardinal dental abnormalities.
Delayed Dentition Delayed eruption of teeth HP:0000684
Show evidence (1 reference)
PMID:22855961 SUPPORT Human Clinical
"Abnormal dentition (delayed dentition, hypodontia, oligodontia, and abnormally placed or shaped teeth)."
GeneReviews lists delayed dentition among the cardinal dental abnormalities.
Musculoskeletal 1
Spasticity Spasticity HP:0001257
Show evidence (1 reference)
PMID:22855961 SUPPORT Human Clinical
"pyramidal [i.e., spasticity]"
GeneReviews lists pyramidal dysfunction manifesting as spasticity.
Nervous System 6
Ataxia VERY_FREQUENT Ataxia HP:0001251
Show evidence (1 reference)
PMID:22855961 SUPPORT Human Clinical
"Neurologic dysfunction, typically predominated by motor dysfunction (progressive cerebellar dysfunction"
GeneReviews documents progressive cerebellar dysfunction as the predominant neurologic feature.
Dystonia Dystonia HP:0001332
Show evidence (1 reference)
PMID:22855961 SUPPORT Human Clinical
"extrapyramidal [i.e., dystonia]"
GeneReviews lists extrapyramidal dysfunction manifesting as dystonia.
Tremor Tremor HP:0001337
Show evidence (1 reference)
PMID:37915380 SUPPORT Human Clinical
"Additional neurological features included cerebellar signs (e.g., dysarthria, ataxia, and intention tremor) and dysphagia"
Supports intention tremor as part of the cerebellar sign cluster in POLR3-related leukodystrophy.
Dysarthria Dysarthria HP:0001260
Show evidence (1 reference)
PMID:37915380 SUPPORT Human Clinical
"Additional neurological features included cerebellar signs (e.g., dysarthria, ataxia, and intention tremor) and dysphagia"
Supports dysarthria as a cerebellar sign in POLR3-related leukodystrophy.
Cognitive Decline Cognitive impairment HP:0100543
Show evidence (1 reference)
PMID:38561452 SUPPORT Human Clinical
"The proband (IV6) in this family mainly showed progressive cognitive decline, dentin dysplasia, and hypogonadotropic hypogonadism."
Documents progressive cognitive decline in a molecularly confirmed HLD7 family.
Developmental Regression Developmental regression HP:0002376
Show evidence (1 reference)
PMID:25339210 SUPPORT Human Clinical
"The majority of patients presented before 6 years with gross motor delay or regression."
Supports motor delay/regression as the typical childhood presentation.
Growth 1
Short Stature FREQUENT Short stature HP:0004322
Show evidence (1 reference)
PMID:22855961 SUPPORT Human Clinical
"Endocrine abnormalities such as short stature (in ~50% of individuals) with or without growth hormone deficiency"
GeneReviews reports short stature in approximately 50% of individuals, supporting the FREQUENT band.
Other 1
CNS Hypomyelination CNS hypomyelination HP:0003429
Show evidence (1 reference)
PMID:25339210 SUPPORT Human Clinical
"the combination of hypomyelination with relative T2 hypointensity of the ventrolateral thalamus, optic radiation, globus pallidus, and dentate nucleus, cerebellar atrophy, and thinning of the corpus callosum suggests the diagnosis."
Documents the hypomyelination MRI pattern across 105 mutation-proven 4H cases.
🧬

Genetic Associations

1
POLR3A (Causative)
Gene: POLR3A hgnc:30074
Autosomal recessive inheritance
Show evidence (2 references)
PMID:38561452 SUPPORT Human Clinical
"The proband and her two living brothers (IV2 and IV4) were detected to carry a homozygous mutation of the POLR3A (NM_007055.4) gene c. 2300G > T (p.Cys767Phe), and her consanguineous married parents (III1 and III2) were p.Cys767Phe heterozygous carriers."
Documents a homozygous POLR3A variant segregating recessively in an HLD7 family with consanguineous parents.
PMID:33597727 SUPPORT Human Clinical
"splice variant POLR3A c.1770 + 5 G > C was proved to disrupt the normal splicing of intron 13 and led to a premature stop codon at position 618 (p.(P591Vfs*28))."
Functionally confirms a POLR3A splice variant identified by trio-based whole-exome sequencing.
💊

Medical Actions

2
Multidisciplinary Supportive Care
Action: supportive care MAXO:0000950
Management is supportive and symptom-directed via a multidisciplinary team (neurology, genetics, physiotherapy, occupational therapy, speech-language pathology, neuropsychology, rehabilitation, dentistry, endocrinology, ophthalmology, ENT). Particular caution is needed managing dysphagia, which can vary widely even within a single day, and dystonia should be monitored and treated to prevent complications.
Target Phenotypes: Ataxia HP:0001251 Spasticity HP:0001257 Dystonia HP:0001332
Show evidence (2 references)
PMID:22855961 SUPPORT Human Clinical
"Individualized care by a multidisciplinary team including a pediatric neurologist, clinical geneticist, physiotherapist, occupational therapist, speech and language pathologist, neuropsychologist, rehabilitation physician, dentist, endocrinologist, ophthalmologist, ear-nose-and-throat..."
GeneReviews specifies multidisciplinary supportive management.
PMID:22855961 SUPPORT Human Clinical
"Special caution needs to be taken when managing dysphagia in this disorder as it is known to vary widely, even in a single day."
Captures the GeneReviews dysphagia management caution.
Genetic Counseling
Action: Genetic Counseling NCIT:C15240
Genetic counseling is appropriate given autosomal recessive inheritance; each sib of an affected individual has a 25% risk. Carrier testing for at-risk relatives and prenatal diagnosis are possible when both familial variants are known.
Show evidence (1 reference)
PMID:22855961 SUPPORT Human Clinical
"Carrier testing for at-risk relatives and prenatal diagnosis for pregnancies at increased risk are possible if both pathogenic variants in the family are known."
GeneReviews supports carrier testing and prenatal diagnosis within genetic counseling.
{ }

Source YAML

click to show 
name: Hypomyelinating Leukodystrophy 7
creation_date: "2026-06-03T00:00:00Z"
category: Mendelian
disease_term:
  preferred_term: POLR3-related (4H) leukodystrophy, POLR3A type (HLD7)
  term:
    id: MONDO:0011897
    label: leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism
description: >-
  Hypomyelinating leukodystrophy 7 (HLD7) is an autosomal recessive
  hypomyelinating leukodystrophy caused by biallelic pathogenic variants in
  POLR3A, the gene encoding the largest, catalytic subunit of RNA polymerase III
  (Pol III). It lies within the POLR3-related leukodystrophy / "4H leukodystrophy"
  spectrum (hypomyelination, hypodontia, hypogonadotropic hypogonadism). Clinically
  it features progressive neurologic dysfunction predominated by cerebellar and
  motor signs (ataxia, spasticity, tremor, dystonia, dysarthria) with cognitive
  decline, plus extra-neurologic dental, endocrine, and ocular involvement and a
  characteristic diffuse-hypomyelination MRI pattern with relative preservation of
  early-myelinating structures.
synonyms:
- HLD7
- 4H syndrome
- 4H leukodystrophy
- POLR3-related leukodystrophy
- POLR3A-related hypomyelinating leukodystrophy
- POLR3-HLD
- Hypomyelination, hypodontia, hypogonadotropic hypogonadism
parents:
- POLR3-related leukodystrophy
external_assertions:
- name: OMIM hypomyelinating leukodystrophy 7 record
  source: OMIM
  assertion_type: disease_record
  external_id: OMIM:607694
  description: OMIM phenotype identifier for hypomyelinating leukodystrophy 7 (HLD7).
has_subtypes:
- name: POLR3A
  display_name: POLR3A-related HLD7
  description: >-
    The canonical HLD7 subtype caused by biallelic pathogenic variants in POLR3A.
    POLR3A-associated disease tends to follow a more severe clinical course than
    POLR3B-related 4H leukodystrophy.
  evidence:
  - reference: PMID:38561452
    reference_title: "Clinical phenotype and genetic function analysis of a family with hypomyelinating leukodystrophy-7 caused by POLR3A mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study aims to analyze the clinical phenotype and genetic function of a family with HLD-7 caused by POLR3A mutation."
    explanation: Defines HLD7 as the POLR3A-caused hypomyelinating leukodystrophy subtype.
  - reference: PMID:25339210
    reference_title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations in POLR3A are associated with a more severe clinical course."
    explanation: Supports POLR3A-related disease as the more severe end of the 4H/POLR3-related leukodystrophy spectrum.
- name: POLR3B
  display_name: POLR3B-related 4H leukodystrophy
  description: >-
    A clinically overlapping POLR3-related leukodystrophy subtype caused by
    biallelic POLR3B variants, generally following a milder disease course than
    POLR3A-related disease; homozygosity for the common c.1568T>A POLR3B allele
    causes a mild phenotype.
  evidence:
  - reference: PMID:25339210
    reference_title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The disease course was milder in patients with POLR3B than in patients with POLR3A mutations."
    explanation: Distinguishes POLR3B-related 4H leukodystrophy as the milder subtype within the spectrum.
  - reference: PMID:25339210
    reference_title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most patients carried the common c.1568T>A POLR3B mutation on one allele, homozygosity for which causes a mild phenotype."
    explanation: Documents the recurrent POLR3B c.1568T>A allele associated with a mild phenotype when homozygous.
pathophysiology:
- name: Biallelic POLR3A Loss of Function
  description: >-
    Biallelic pathogenic variants in POLR3A (the largest, catalytic subunit of
    RNA polymerase III) impair Pol III, the enzyme that transcribes many small
    non-coding RNAs including tRNAs and 5S rRNA. This is the proximal molecular
    lesion of HLD7.
  biological_processes:
  - preferred_term: transcription by RNA polymerase III
    term:
      id: GO:0006383
      label: transcription by RNA polymerase III
    modifier: DECREASED
  evidence:
  - reference: PMID:38561452
    reference_title: "Clinical phenotype and genetic function analysis of a family with hypomyelinating leukodystrophy-7 caused by POLR3A mutation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "overexpression of wild-type POLR3A protein significantly enhanced Pol III transcription of 5S rRNA and tRNA Leu-CAA."
    explanation: Establishes POLR3A as a determinant of Pol III transcription, the activity impaired by HLD7 variants.
  - reference: PMID:36140376
    reference_title: "Identification of a Novel Missense Mutation of POLR3A Gene in a Cohort of Sicilian Patients with Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Recessive mutations in the POLR3A gene cause POLR3-HLD (the second-most-common form of childhood-onset hypomyelinating leukodystrophy), a neurodegenerative disorder featuring deficient cerebral myelin formation."
    explanation: Supports recessive POLR3A variants as the cause of POLR3-HLD with deficient myelin formation.
  downstream:
  - target: Impaired Pol III Transcript Output
    description: Defective Pol III lowers production of its small non-coding RNA transcripts (tRNAs, 5S rRNA).
- name: Impaired Pol III Transcript Output
  description: >-
    The mutant POLR3A protein fails to support normal Pol III activity, reducing
    Pol III transcript outputs (e.g., tRNA Leu-CAA, BC200) and downstream
    readouts of myelin biology, linking transcriptional dysfunction to reduced
    myelin basic protein expression.
  biological_processes:
  - preferred_term: tRNA transcription by RNA polymerase III
    term:
      id: GO:0042797
      label: tRNA transcription by RNA polymerase III
    modifier: DECREASED
  evidence:
  - reference: PMID:38561452
    reference_title: "Clinical phenotype and genetic function analysis of a family with hypomyelinating leukodystrophy-7 caused by POLR3A mutation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Pol III transcription function was frustrated (POLR3A, BC200, and tRNA Leu-CAA expression decreased), and MBP and 18S rRNA expressions were decreased."
    explanation: Directly links the POLR3A p.Cys767Phe variant to reduced Pol III transcripts and decreased myelin basic protein expression.
  - reference: PMID:37915380
    reference_title: "Biallelic pathogenic variants in POLR3D alter tRNA transcription and cause a hypomyelinating leukodystrophy: A case report."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Pol III transcription was also shown to be aberrant, with a significant decrease in 7SK RNA and several distinct tRNA genes"
    explanation: Supports reduced Pol III tRNA output as a shared mechanism across POLR3-related leukodystrophies.
  downstream:
  - target: Oligodendrocyte and Myelin Dysfunction
    description: Reduced Pol III transcript supply perturbs oligodendrocyte translation and myelin production.
- name: Oligodendrocyte and Myelin Dysfunction
  description: >-
    Reduced Pol III transcript supply is hypothesized to impair oligodendrocyte
    differentiation and the high translational demand of myelin protein synthesis,
    yielding deficient central nervous system myelination.
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: oligodendrocyte differentiation
    term:
      id: GO:0048709
      label: oligodendrocyte differentiation
    modifier: ABNORMAL
  - preferred_term: central nervous system myelination
    term:
      id: GO:0022010
      label: central nervous system myelination
    modifier: DECREASED
  evidence:
  - reference: PMID:36140376
    reference_title: "Identification of a Novel Missense Mutation of POLR3A Gene in a Cohort of Sicilian Patients with Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a neurodegenerative disorder featuring deficient cerebral myelin formation."
    explanation: Supports deficient cerebral myelin formation as the cellular/tissue-level consequence in POLR3-HLD.
  - reference: PMID:37755363
    reference_title: "Molecular Pathogenic Mechanisms of Hypomyelinating Leukodystrophies (HLDs)."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "An increasing number of studies have reported genetic mutations that cause protein misfolding, protein dysfunction, and/or mislocalization associated with HLD."
    explanation: Supports protein dysfunction as the mechanistic theme underlying hypomyelinating leukodystrophies including POLR3-related disease.
  downstream:
  - target: Central Nervous System Hypomyelination
    description: Oligodendrocyte and myelin dysfunction manifests as diffuse CNS hypomyelination.
- name: Central Nervous System Hypomyelination
  description: >-
    Diffuse hypomyelination of central nervous system white matter, with relative
    preservation of early-myelinating structures, is the defining tissue-level
    output and produces the characteristic brain MRI pattern of POLR3-related
    leukodystrophy.
  biological_processes:
  - preferred_term: myelination
    term:
      id: GO:0042552
      label: myelination
    modifier: DECREASED
  evidence:
  - reference: PMID:25339210
    reference_title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the combination of hypomyelination with relative T2 hypointensity of the ventrolateral thalamus, optic radiation, globus pallidus, and dentate nucleus, cerebellar atrophy, and thinning of the corpus callosum suggests the diagnosis."
    explanation: Describes the diffuse hypomyelination pattern that defines the disease at the tissue/imaging level.
  - reference: PMID:37915380
    reference_title: "Biallelic pathogenic variants in POLR3D alter tRNA transcription and cause a hypomyelinating leukodystrophy: A case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Her MRI was notable for diffuse hypomyelination with myelin preservation of early myelinating structures, characteristic of POLR3-related leukodystrophy."
    explanation: Supports diffuse hypomyelination with preservation of early-myelinating structures as characteristic of POLR3-related leukodystrophy.
phenotypes:
- name: CNS Hypomyelination
  category: Neurologic
  phenotype_term:
    preferred_term: CNS hypomyelination
    term:
      id: HP:0003429
      label: CNS hypomyelination
  description: >-
    Diffuse central nervous system hypomyelination on brain MRI is the defining
    radiologic feature, with relative preservation of early-myelinating
    structures.
  evidence:
  - reference: PMID:25339210
    reference_title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the combination of hypomyelination with relative T2 hypointensity of the ventrolateral thalamus, optic radiation, globus pallidus, and dentate nucleus, cerebellar atrophy, and thinning of the corpus callosum suggests the diagnosis."
    explanation: Documents the hypomyelination MRI pattern across 105 mutation-proven 4H cases.
- name: Ataxia
  category: Neurologic
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  description: >-
    Progressive cerebellar dysfunction with ataxia is a predominant neurologic
    feature of POLR3-related leukodystrophy.
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurologic dysfunction, typically predominated by motor dysfunction (progressive cerebellar dysfunction"
    explanation: GeneReviews documents progressive cerebellar dysfunction as the predominant neurologic feature.
- name: Spasticity
  category: Neurologic
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  description: Pyramidal involvement produces spasticity as part of the motor syndrome.
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "pyramidal [i.e., spasticity]"
    explanation: GeneReviews lists pyramidal dysfunction manifesting as spasticity.
- name: Dystonia
  category: Neurologic
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  description: Extrapyramidal involvement can produce dystonia.
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "extrapyramidal [i.e., dystonia]"
    explanation: GeneReviews lists extrapyramidal dysfunction manifesting as dystonia.
- name: Tremor
  category: Neurologic
  phenotype_term:
    preferred_term: Tremor
    term:
      id: HP:0001337
      label: Tremor
  description: Intention tremor is part of the cerebellar motor phenotype.
  evidence:
  - reference: PMID:37915380
    reference_title: "Biallelic pathogenic variants in POLR3D alter tRNA transcription and cause a hypomyelinating leukodystrophy: A case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additional neurological features included cerebellar signs (e.g., dysarthria, ataxia, and intention tremor) and dysphagia"
    explanation: Supports intention tremor as part of the cerebellar sign cluster in POLR3-related leukodystrophy.
- name: Dysarthria
  category: Neurologic
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  description: Cerebellar dysfunction produces dysarthria.
  evidence:
  - reference: PMID:37915380
    reference_title: "Biallelic pathogenic variants in POLR3D alter tRNA transcription and cause a hypomyelinating leukodystrophy: A case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additional neurological features included cerebellar signs (e.g., dysarthria, ataxia, and intention tremor) and dysphagia"
    explanation: Supports dysarthria as a cerebellar sign in POLR3-related leukodystrophy.
- name: Cognitive Decline
  category: Neurologic
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  description: >-
    Cognitive dysfunction, including progressive cognitive decline/regression,
    is common.
  evidence:
  - reference: PMID:38561452
    reference_title: "Clinical phenotype and genetic function analysis of a family with hypomyelinating leukodystrophy-7 caused by POLR3A mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The proband (IV6) in this family mainly showed progressive cognitive decline, dentin dysplasia, and hypogonadotropic hypogonadism."
    explanation: Documents progressive cognitive decline in a molecularly confirmed HLD7 family.
- name: Developmental Regression
  category: Neurologic
  phenotype_term:
    preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  description: >-
    Many patients present in early childhood with gross motor delay or
    regression.
  evidence:
  - reference: PMID:25339210
    reference_title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The majority of patients presented before 6 years with gross motor delay or regression."
    explanation: Supports motor delay/regression as the typical childhood presentation.
- name: Oligodontia
  category: Dental
  phenotype_term:
    preferred_term: Oligodontia
    term:
      id: HP:0000677
      label: Oligodontia
  description: >-
    Abnormal dentition including hypodontia and oligodontia is a cardinal
    extra-neurologic feature.
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Abnormal dentition (delayed dentition, hypodontia, oligodontia, and abnormally placed or shaped teeth)."
    explanation: GeneReviews lists oligodontia among the cardinal dental abnormalities.
- name: Delayed Dentition
  category: Dental
  phenotype_term:
    preferred_term: Delayed eruption of teeth
    term:
      id: HP:0000684
      label: Delayed eruption of teeth
  description: Delayed dentition is part of the abnormal dental phenotype.
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Abnormal dentition (delayed dentition, hypodontia, oligodontia, and abnormally placed or shaped teeth)."
    explanation: GeneReviews lists delayed dentition among the cardinal dental abnormalities.
- name: Hypogonadotropic Hypogonadism
  category: Endocrine
  phenotype_term:
    preferred_term: Hypogonadotropic hypogonadism
    term:
      id: HP:0000044
      label: Hypogonadotropic hypogonadism
  description: >-
    Hypogonadotropic hypogonadism, manifesting as delayed, arrested, or absent
    puberty, is the most common endocrine feature.
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "more commonly, hypogonadotropic hypogonadism manifesting as delayed, arrested, or absent puberty."
    explanation: GeneReviews documents hypogonadotropic hypogonadism as the common endocrine manifestation.
- name: Short Stature
  category: Endocrine
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  description: >-
    Short stature, with or without growth hormone deficiency, occurs in about
    half of individuals.
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Endocrine abnormalities such as short stature (in ~50% of individuals) with or without growth hormone deficiency"
    explanation: GeneReviews reports short stature in approximately 50% of individuals, supporting the FREQUENT band.
- name: Myopia
  category: Ophthalmologic
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Myopia
    term:
      id: HP:0000545
      label: Myopia
  description: >-
    Progressive myopia, often becoming severe, is a near-universal ocular
    feature.
  evidence:
  - reference: PMID:25339210
    reference_title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other than the typical neurologic, dental, and endocrine features, myopia was seen in almost all and short stature in 50%."
    explanation: Reports myopia in almost all patients, supporting the VERY_FREQUENT band.
genetic:
- name: POLR3A
  gene_term:
    preferred_term: POLR3A
    term:
      id: hgnc:30074
      label: POLR3A
  association: Causative
  features: >-
    Biallelic (homozygous or compound heterozygous) pathogenic variants in
    POLR3A, encoding the largest catalytic subunit of RNA polymerase III, cause
    HLD7. Reported variant classes include missense, splice-region, frameshift,
    and in-frame insertion variants.
  inheritance:
  - name: Autosomal recessive inheritance
    evidence:
    - reference: PMID:22855961
      reference_title: "POLR3-Related Leukodystrophy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "POLR3-related leukodystrophy is inherited in an autosomal recessive manner."
      explanation: GeneReviews establishes autosomal recessive inheritance.
  evidence:
  - reference: PMID:38561452
    reference_title: "Clinical phenotype and genetic function analysis of a family with hypomyelinating leukodystrophy-7 caused by POLR3A mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The proband and her two living brothers (IV2 and IV4) were detected to carry a homozygous mutation of the POLR3A (NM_007055.4) gene c. 2300G > T (p.Cys767Phe), and her consanguineous married parents (III1 and III2) were p.Cys767Phe heterozygous carriers."
    explanation: Documents a homozygous POLR3A variant segregating recessively in an HLD7 family with consanguineous parents.
  - reference: PMID:33597727
    reference_title: "Genetic analysis of 20 patients with hypomyelinating leukodystrophy by trio-based whole-exome sequencing."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "splice variant POLR3A c.1770 + 5 G > C was proved to disrupt the normal splicing of intron 13 and led to a premature stop codon at position 618 (p.(P591Vfs*28))."
    explanation: Functionally confirms a POLR3A splice variant identified by trio-based whole-exome sequencing.
diagnosis:
- name: Characteristic Brain MRI Pattern
  diagnosis_term:
    preferred_term: magnetic resonance imaging procedure
    term:
      id: MAXO:0000424
      label: magnetic resonance imaging procedure
  description: >-
    Brain MRI pattern recognition is central to diagnosis: diffuse hypomyelination
    with relative T2 hypointensity of the ventrolateral thalamus, optic radiation,
    globus pallidus, and dentate nucleus, cerebellar atrophy, and thinning of the
    corpus callosum.
  results: >-
    The characteristic hypomyelination pattern, especially when cardinal
    non-neurologic features are absent, suggests POLR3-related leukodystrophy.
  evidence:
  - reference: PMID:25339210
    reference_title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MRI characteristics are helpful in addressing the diagnosis, especially if patients lack the cardinal non-neurologic features."
    explanation: Supports MRI pattern recognition as a key diagnostic tool.
  - reference: PMID:29179231
    reference_title: "4H Leukodystrophy: Lessons from 3T Imaging."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Novel MRI findings were myelin islets, closed eye sign, and a cyst-like lesion in the splenium."
    explanation: Adds higher-field 3T MRI features that aid diagnosis of 4H leukodystrophy.
- name: Molecular Genetic Testing
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: MAXO:0000127
      label: genetic testing
  description: >-
    Diagnosis is confirmed by detecting biallelic pathogenic variants in POLR3A
    (or POLR3B/POLR1C), typically via exome or trio-based whole-exome sequencing.
  results: >-
    Biallelic pathogenic POLR3A variants confirm HLD7.
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "POLR3-related leukodystrophy is diagnosed by the combination of classic clinical findings, typical brain MRI features, and the presence of biallelic pathogenic variants in POLR3A, POLR3B, or POLR1C."
    explanation: GeneReviews defines the molecular diagnostic criteria.
  - reference: PMID:33597727
    reference_title: "Genetic analysis of 20 patients with hypomyelinating leukodystrophy by trio-based whole-exome sequencing."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It emphasizes the heterogenicity of HLDs, the diagnostic power of trio-based WES for HLDs."
    explanation: Supports trio-based whole-exome sequencing as an effective diagnostic approach.
treatments:
- name: Multidisciplinary Supportive Care
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  description: >-
    Management is supportive and symptom-directed via a multidisciplinary team
    (neurology, genetics, physiotherapy, occupational therapy, speech-language
    pathology, neuropsychology, rehabilitation, dentistry, endocrinology,
    ophthalmology, ENT). Particular caution is needed managing dysphagia, which
    can vary widely even within a single day, and dystonia should be monitored
    and treated to prevent complications.
  target_phenotypes:
  - preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  - preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  - preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Individualized care by a multidisciplinary team including a pediatric neurologist, clinical geneticist, physiotherapist, occupational therapist, speech and language pathologist, neuropsychologist, rehabilitation physician, dentist, endocrinologist, ophthalmologist, ear-nose-and-throat specialist, and primary care physician is recommended."
    explanation: GeneReviews specifies multidisciplinary supportive management.
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Special caution needs to be taken when managing dysphagia in this disorder as it is known to vary widely, even in a single day."
    explanation: Captures the GeneReviews dysphagia management caution.
- name: Genetic Counseling
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  description: >-
    Genetic counseling is appropriate given autosomal recessive inheritance; each
    sib of an affected individual has a 25% risk. Carrier testing for at-risk
    relatives and prenatal diagnosis are possible when both familial variants are
    known.
  evidence:
  - reference: PMID:22855961
    reference_title: "POLR3-Related Leukodystrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Carrier testing for at-risk relatives and prenatal diagnosis for pregnancies at increased risk are possible if both pathogenic variants in the family are known."
    explanation: GeneReviews supports carrier testing and prenatal diagnosis within genetic counseling.
references:
- reference: PMID:22855961
  title: "POLR3-Related Leukodystrophy."
  tags:
  - GeneReviews
- reference: PMID:38561452
  title: "Clinical phenotype and genetic function analysis of a family with hypomyelinating leukodystrophy-7 caused by POLR3A mutation."
  findings: []
- reference: PMID:25339210
  title: "Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations."
  findings: []
- reference: PMID:33597727
  title: "Genetic analysis of 20 patients with hypomyelinating leukodystrophy by trio-based whole-exome sequencing."
  findings: []
- reference: PMID:36140376
  title: "Identification of a Novel Missense Mutation of POLR3A Gene in a Cohort of Sicilian Patients with Leukodystrophy."
  findings: []
- reference: PMID:32600288
  title: "A novel POLR3A genotype leads to leukodystrophy type-7 in two siblings with unusually late age of onset."
  findings: []
- reference: PMID:29179231
  title: "4H Leukodystrophy: Lessons from 3T Imaging."
  findings: []
- reference: PMID:37915380
  title: "Biallelic pathogenic variants in POLR3D alter tRNA transcription and cause a hypomyelinating leukodystrophy: A case report."
  findings: []
- reference: PMID:37755363
  title: "Molecular Pathogenic Mechanisms of Hypomyelinating Leukodystrophies (HLDs)."
  findings: []
- reference: PMID:39062571
  title: "Towards a Treatment for Leukodystrophy Using Cell-Based Interception and Precision Medicine."
  findings: []
📚

References & Deep Research

References

10
PMID:22855961
POLR3-Related Leukodystrophy.
No top-level findings curated for this source.
PMID:38561452
Clinical phenotype and genetic function analysis of a family with hypomyelinating leukodystrophy-7 caused by POLR3A mutation.
No top-level findings curated for this source.
PMID:25339210
Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations.
No top-level findings curated for this source.
PMID:33597727
Genetic analysis of 20 patients with hypomyelinating leukodystrophy by trio-based whole-exome sequencing.
No top-level findings curated for this source.
PMID:36140376
Identification of a Novel Missense Mutation of POLR3A Gene in a Cohort of Sicilian Patients with Leukodystrophy.
No top-level findings curated for this source.
PMID:32600288
A novel POLR3A genotype leads to leukodystrophy type-7 in two siblings with unusually late age of onset.
No top-level findings curated for this source.
PMID:29179231
4H Leukodystrophy: Lessons from 3T Imaging.
No top-level findings curated for this source.
PMID:37915380
Biallelic pathogenic variants in POLR3D alter tRNA transcription and cause a hypomyelinating leukodystrophy: A case report.
No top-level findings curated for this source.
PMID:37755363
Molecular Pathogenic Mechanisms of Hypomyelinating Leukodystrophies (HLDs).
No top-level findings curated for this source.
PMID:39062571
Towards a Treatment for Leukodystrophy Using Cell-Based Interception and Precision Medicine.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Hypomyelinating Leukodystrophy 7 (HLD7) — Disease Characteristics Research Report
Edison Scientific Literature 30 citations 2026-06-03T23:50:20.159868

Hypomyelinating Leukodystrophy 7 (HLD7) — Disease Characteristics Research Report

Executive summary

Hypomyelinating leukodystrophy 7 (HLD7) is an autosomal recessive, POLR3A-associated hypomyelinating leukodystrophy within the POLR3-related leukodystrophy/“4H leukodystrophy” spectrum, characterized by central nervous system hypomyelination and frequent extra-neurologic dental and endocrine involvement. Key diagnostic clues are a characteristic brain MRI pattern plus confirmatory biallelic POLR3A variants. Recent (2023–2024) work emphasizes mechanistic links between POLR3A dysfunction, abnormal RNA polymerase III transcript output, and impaired myelin biology, and calls for precision-medicine approaches (single-cell omics, cell-based drug screening) to enable future targeted therapies. (torii2023molecularpathogenicmechanisms pages 1-2, wolf2014clinicalspectrumof pages 1-2, macintosh2023biallelicpathogenicvariants pages 1-2, ruan2024clinicalphenotypeand pages 1-2)

Category Summary
Disease identifiers / synonyms / inheritance HLD7 is listed as Hypomyelinating leukodystrophy 7 with OMIM/MIM 607694; it is also described within 4H leukodystrophy and broader POLR3-related leukodystrophy / POLR3-HLD nomenclature. Core synonym expansion of 4H is hypomyelination, hypodontia, and hypogonadotropic hypogonadism. Inheritance is autosomal recessive / biallelic. Evidence note: multiple sources converge on HLD7 as the POLR3A-associated recessive 4H/POLR3-HLD entity. (lynch2022clinicalandgenetic pages 42-46, torii2023molecularpathogenicmechanisms pages 1-2, cayami20184hleukodystrophylessons pages 1-2, wolf2014clinicalspectrumof pages 1-2, macintosh2023biallelicpathogenicvariants pages 1-2)
Causal gene Primary causal gene for HLD7 is POLR3A (RNA polymerase III subunit A; gene OMIM 614258), encoding the largest/catalytic core Pol III subunit involved in transcription of small non-coding RNAs including tRNAs and 5S rRNA. Related POLR3-HLD genes mentioned across the disease spectrum include POLR3B, POLR1C, POLR3K, and newer POLR3-related causes such as POLR3D, but HLD7 specifically maps to POLR3A*. Evidence note: human genetic and functional studies consistently support POLR3A as the HLD7 gene. (ruan2024clinicalphenotypeand pages 1-2, yan2021geneticanalysisof pages 4-6, torii2023molecularpathogenicmechanisms pages 1-2, macintosh2023biallelicpathogenicvariants pages 1-2)
Hallmark clinical features and MRI pattern Hallmark neurologic features include motor delay/decline, spasticity, ataxia, tremor, dystonia, dysarthria, cerebellar signs, cognitive impairment/regression; extra-neurologic features include hypodontia/dental anomalies (including dentin dysplasia), hypogonadotropic hypogonadism, short stature, ocular findings. MRI pattern typically shows diffuse hypomyelination with relative preservation of early-myelinating structures such as the optic radiations, ventrolateral thalamus, globus pallidus/dentate nucleus, plus cerebellar atrophy and thinning/atrophy of the corpus callosum; newer 3T descriptions include the closed eye sign and myelin islets. Evidence note: the classic 4H triad remains diagnostically useful, but phenotype and MRI severity are variable and diffuse hypomyelination is not obligatory in every POLR3-related presentation. (wu2019novelmutationsof pages 1-4, campopiano2020anovelpolr3a pages 1-2, cayami20184hleukodystrophylessons pages 1-2, wolf2014clinicalspectrumof pages 1-2, macintosh2023biallelicpathogenicvariants pages 1-2, ruan2024clinicalphenotypeand pages 12-13, ruan2024clinicalphenotypeand pages 1-2)
Example pathogenic variants Representative POLR3A variants reported in HLD7/POLR3-HLD include c.2300G>T (p.Cys767Phe) in a homozygous family with functional impairment of Pol III transcription; c.1771-6C>G and c.2611del (p.M871Cfs*8) as compound heterozygous variants in a Chinese case; c.661_662insCCT (p.P220_L221insS) with c.1770+5G>C causing aberrant splicing and p.(P591Vfs*28); and a novel missense c.328A>G (p.Lys110Glu) in severe POLR3-related leukodystrophy. Evidence note: reported variant classes include missense, frameshift, splice-region, and in-frame insertion variants, reinforcing allelic heterogeneity. (ruan2024clinicalphenotypeand pages 1-2, yan2021geneticanalysisof pages 4-6, wu2019novelmutationsof pages 4-6, musumeci2022identificationofa pages 3-5)
Key recent advances (2023–2024) Recent work refined disease biology and heterogeneity: a 2023 review summarized HLD molecular mechanisms and confirmed HLD7/POLR3A as part of the expanding hypomyelinating leukodystrophy landscape; a 2024 family study showed p.Cys767Phe impairs Pol III outputs and lowers MBP and 18S rRNA expression; 2024 precision-medicine work proposed single-cell omics and drug screening for leukodystrophies; and a 2024 mouse study supported tRNA reduction, innate immune/integrated stress responses, oligodendrocyte loss, neuron loss, and microglial activation as candidate disease mechanisms in Polr3-related disease. Evidence note: the field is shifting from descriptive genetics toward mechanism-based stratification and therapy discovery, though disease-specific interventional trials for HLD7 were not identified in the provided evidence. (ruan2024clinicalphenotypeand pages 1-2, coulombe2024towardsatreatment pages 8-9, coulombe2024towardsatreatment pages 2-4, coulombe2024towardsatreatment pages 4-5)
Model systems / translational clues Model systems include mouse oligodendroglial FBD-102b cells expressing HLD7-associated POLR3A R140X, where mutant protein localized to lysosomes, reduced mTOR signaling, and impaired oligodendroglial differentiation; ibuprofen partially ameliorated these cellular defects in vitro. In vivo, an earlier Polr3a G672E mouse failed to recapitulate major neurologic/myelin phenotypes, highlighting model limitations, whereas a newer postnatal whole-body Polr3a mutant mouse showed behavioral deficits, cerebral pathology, altered tRNA pools, oligodendrocyte/neuron loss, and microglial activation. Evidence note: model systems support oligodendrocyte maturation failure as a central mechanism, but phenotypic fidelity depends strongly on allele/model design. (torii2023molecularpathogenicmechanisms pages 1-2, coulombe2024towardsatreatment pages 4-5, ruan2024clinicalphenotypeand pages 1-2)

Table: This table condenses the key disease-level facts for Hypomyelinating Leukodystrophy 7, including identifiers, gene, phenotype, MRI, representative variants, and recent mechanistic/model advances. It is useful as a compact evidence-backed reference for building a disease knowledge base entry.

1. Disease information

1.1 Definition/overview

HLD7 is described as an autosomal recessive neurodegenerative disorder with childhood-onset progressive motor decline and CNS hypomyelination, historically grouped under “4H leukodystrophy” (hypomyelination, hypodontia, hypogonadotropic hypogonadism) and broader “POLR3-related leukodystrophy / POLR3-HLD” terminology. (wu2019novelmutationsof pages 1-4, wu2019novelmutationsof pages 4-6, macintosh2023biallelicpathogenicvariants pages 1-2)

Direct abstract-anchored definition examples: - “Hypomyelinating leukodystrophy 7 (HLD7) is an autosomal recessive neurodegenerative disorder” (case report text) (wu2019novelmutationsof pages 4-6). - 4H leukodystrophy is “typically characterized by the triad of hypomyelination, hypodontia, and hypogonadotropic hypogonadism.” (wolf2014clinicalspectrumof pages 1-2)

1.2 Key identifiers

  • OMIM/MIM disease ID: 607694 (HLD7) (lynch2022clinicalandgenetic pages 42-46, torii2023molecularpathogenicmechanisms pages 1-2, cayami20184hleukodystrophylessons pages 1-2, wolf2014clinicalspectrumof pages 1-2)
  • Causal gene: POLR3A (see Genetics section) (lynch2022clinicalandgenetic pages 42-46, torii2023molecularpathogenicmechanisms pages 1-2)
  • MONDO / Orphanet / ICD / MeSH: Not available from the retrieved primary sources in this run; should be pulled from OMIM/Orphanet/MONDO directly during KB curation (not reliably inferable from the present evidence set).

1.3 Synonyms and alternative names

Commonly used overlapping terms in the literature: - Hypomyelinating leukodystrophy 7 (HLD7) (torii2023molecularpathogenicmechanisms pages 1-2) - 4H leukodystrophy (wolf2014clinicalspectrumof pages 1-2) - POLR3-related leukodystrophy / POLR3-HLD (macintosh2023biallelicpathogenicvariants pages 1-2) - In adult leukoencephalopathy differential-diagnosis tables, HLD7 is also labeled by its classic triad: “Hypomyelination, hypogonadotropic hypogonadism and hypodontia.” (lynch2022clinicalandgenetic pages 42-46)

1.4 Evidence source types

Evidence summarized here is primarily from: - Aggregated disease-level resources (reviews and cross-sectional case series) (torii2023molecularpathogenicmechanisms pages 1-2, wolf2014clinicalspectrumof pages 1-2) - Individual/family case reports with functional follow-up (ruan2024clinicalphenotypeand pages 1-2, wu2019novelmutationsof pages 4-6) - Diagnostic cohort sequencing studies (WES-based molecular diagnosis) (yan2021geneticanalysisof pages 4-6)

2. Etiology

2.1 Disease causal factors

Genetic (primary): HLD7 is caused by biallelic pathogenic variants in POLR3A, encoding the largest subunit of RNA polymerase III (Pol III), which transcribes many small non-coding RNAs including tRNAs and 5S rRNA. (yan2021geneticanalysisof pages 4-6, torii2023molecularpathogenicmechanisms pages 1-2, ruan2024clinicalphenotypeand pages 1-2)

Disease context: HLD7 sits within the broader POLR3-related leukodystrophy group arising from biallelic variants in Pol III subunit genes, including POLR3A and other subunits (e.g., POLR3B, POLR1C, POLR3K; and newer causes such as POLR3D). (ruan2024clinicalphenotypeand pages 1-2, macintosh2023biallelicpathogenicvariants pages 1-2)

2.2 Risk factors

  • Family history / consanguinity increases likelihood because inheritance is autosomal recessive; an HLD7 family report explicitly involved consanguineous parents who were heterozygous carriers while affected siblings were homozygous. (ruan2024clinicalphenotypeand pages 1-2)

No robust, disease-specific environmental risk factors were identified in the retrieved evidence set.

2.3 Protective factors

No genetic or environmental protective factors were identified in the retrieved evidence set.

2.4 Gene–environment interactions

No HLD7-specific gene–environment interactions were identified in the retrieved evidence set.

3. Phenotypes (clinical features)

3.1 Neurologic phenotypes (symptoms/signs)

Typical neurologic manifestations described across case series/case reports include: - Progressive motor impairment with spasticity, ataxia, tremor, dystonia, dysarthria (wu2019novelmutationsof pages 1-4, wu2019novelmutationsof pages 4-6, ruan2024clinicalphenotypeand pages 1-2) - Cognitive impairment/regression (wu2019novelmutationsof pages 4-6, ruan2024clinicalphenotypeand pages 1-2)

Direct quote example (case report): progressive motor decline manifests as “spasticity, ataxia, tremor, and cerebellar symptoms, as well as mild cognitive regression.” (wu2019novelmutationsof pages 4-6)

Age of onset / course: Onset can vary from childhood to adulthood; unusually late onset has been documented in siblings with first symptoms at ages 19 and 41, highlighting phenotypic heterogeneity. (campopiano2020anovelpolr3a pages 1-2)

3.2 Extra-neurologic phenotypes

Common extra-neurologic features in the POLR3-related/4H spectrum include: - Dental anomalies (hypodontia/hypodontia spectrum; dentin dysplasia) (wolf2014clinicalspectrumof pages 1-2, ruan2024clinicalphenotypeand pages 1-2) - Hypogonadotropic hypogonadism (wolf2014clinicalspectrumof pages 1-2, ruan2024clinicalphenotypeand pages 1-2)

Example from a 2024 family study: proband had “progressive cognitive decline, dentin dysplasia, and hypogonadotropic hypogonadism.” (ruan2024clinicalphenotypeand pages 1-2)

3.3 Imaging phenotypes (MRI)

A key disease concept is that HLD7 is defined by hypomyelination on MRI with a pattern that helps distinguish POLR3-related leukodystrophy from other hypomyelinating disorders: - Pattern description (cross-sectional series): “hypomyelination with relative T2 hypointensity of the ventrolateral thalamus, optic radiation, globus pallidus, and dentate nucleus, cerebellar atrophy, and thinning of the corpus callosum.” (wolf2014clinicalspectrumof pages 1-2) - 3T imaging series: “a relatively hypointense signal of the optic radiation, the ventrolateral thalamus, part of the posterior limb of the internal capsule(PLIC) and the dentate nucleus.” (cayami20184hleukodystrophylessons pages 1-2)

Example from a 2024 family study: MRI showed “bilateral periventricular white matter atrophy, brain atrophy, and corpus callosum atrophy and thinning.” (ruan2024clinicalphenotypeand pages 1-2)

3.4 Suggested HPO terms (non-exhaustive)

(Concept-to-HPO mapping suggestions; frequencies not consistently available in the evidence set) - Hypomyelination (HP:0003429) - Leukodystrophy (HP:0002415) - Ataxia (HP:0001251) - Spasticity (HP:0001257) - Tremor (HP:0001337) - Dystonia (HP:0001332) - Dysarthria (HP:0001260) - Cognitive impairment / intellectual disability (HP:0100543 / HP:0001249) - Hypodontia (HP:0000668) - Hypogonadotropic hypogonadism (HP:0000041)

3.5 Quality of life impact

Formal QoL instruments were not identified in the retrieved evidence set; however, severe motor disability and cognitive regression (e.g., tetraparesis in late-onset siblings) implies major impact on activities of daily living. (campopiano2020anovelpolr3a pages 1-2)

4. Genetic / molecular information

4.1 Causal gene(s)

  • POLR3A (RNA polymerase III subunit A; Pol III catalytic core component) is consistently implicated as the causal gene for HLD7 (MIM 607694). (yan2021geneticanalysisof pages 4-6, lynch2022clinicalandgenetic pages 42-46, torii2023molecularpathogenicmechanisms pages 1-2)

4.2 Pathogenic variants (examples; not exhaustive)

Variant classes observed: missense, splice-region/splice-altering, frameshift, and in-frame insertion variants are reported. (ruan2024clinicalphenotypeand pages 1-2, yan2021geneticanalysisof pages 4-6, wu2019novelmutationsof pages 4-6, musumeci2022identificationofa pages 3-5)

Representative examples with nomenclature: - POLR3A NM_007055.4: c.2300G>T (p.Cys767Phe), homozygous in affected siblings from a consanguineous family. (ruan2024clinicalphenotypeand pages 1-2) - POLR3A c.1771-6C>G (splice-region) and c.2611del (p.M871Cfs*8) as compound heterozygous variants. (wu2019novelmutationsof pages 4-6) - Trio-WES cohort: c.661_662insCCT (p.(P220_L221insS)) and c.1770+5G>C, with splicing disruption leading to p.(P591Vfs*28). (yan2021geneticanalysisof pages 4-6) - Cohort report of severe POLR3-related leukodystrophy: novel missense c.328A>G (p.Lys110Glu) described as “Likely Pathogenic” by the authors. (musumeci2022identificationofa pages 3-5)

Variant prevalence statistic (disease-spectrum level): in a 105-patient mutation-proven series, a recurrent POLR3B allele (not POLR3A) was highlighted (c.1568T>A) and associated with milder phenotypes when homozygous, reinforcing gene- and allele-dependent severity differences across POLR3-related leukodystrophy. (wolf2014clinicalspectrumof pages 1-2)

4.3 Functional consequences (human functional studies)

A 2024 family study provided direct functional evidence for a POLR3A missense allele: - Wild-type POLR3A overexpression enhanced Pol III transcription (5S rRNA and tRNA Leu-CAA), whereas the p.Cys767Phe mutant showed impaired Pol III transcription, with reduced Pol III transcript outputs and decreased MBP expression. (ruan2024clinicalphenotypeand pages 1-2)

4.4 Modifier genes, epigenetics, chromosomal abnormalities

No HLD7-specific modifier genes, epigenetic mechanisms, or chromosomal abnormalities were identified in the retrieved evidence set.

5. Environmental information

No disease-specific environmental/lifestyle/infectious contributors were identified in the retrieved evidence set. HLD7 is primarily genetic. (wu2019novelmutationsof pages 4-6)

6. Mechanism / pathophysiology

6.1 Current understanding (causal chain)

1) Biallelic POLR3A variants impair Pol III function (core transcriptional machinery for many small non-coding RNAs). (ruan2024clinicalphenotypeand pages 1-2) 2) This leads to abnormal Pol III transcript output (e.g., altered 5S rRNA, tRNAs; in the 2024 family study, decreased POLR3A/BC200/tRNA Leu-CAA signals and decreased MBP/18S rRNA readouts were reported). (ruan2024clinicalphenotypeand pages 1-2) 3) Downstream, impaired RNA homeostasis and translation-related processes are hypothesized to perturb oligodendrocyte and myelin biology, yielding hypomyelination and progressive neurologic dysfunction, consistent with the clinical and MRI phenotype. (torii2023molecularpathogenicmechanisms pages 1-2, ruan2024clinicalphenotypeand pages 1-2)

6.2 Suggested ontology terms

GO Biological Process (suggestions): - tRNA transcription by RNA polymerase III (GO:0006383) - 5S rRNA transcription (GO:0009303) - Oligodendrocyte differentiation (GO:0048709) - Central nervous system myelination (GO:0022010)

Cell Ontology (CL) (suggestions): - Oligodendrocyte (CL:0000128) - Oligodendrocyte precursor cell (OPC) (CL:0002453)

7. Anatomical structures affected

7.1 Organ/system level

  • Primary system affected: central nervous system (brain white matter), consistent with leukodystrophy/hypomyelination definitions and MRI findings. (torii2023molecularpathogenicmechanisms pages 1-2, wolf2014clinicalspectrumof pages 1-2)

7.2 Tissue/cell level

  • White matter / myelin and the oligodendrocyte lineage are central to disease expression as inferred from the hypomyelination phenotype and mechanistic framing in POLR3-HLD literature. (torii2023molecularpathogenicmechanisms pages 1-2, ruan2024clinicalphenotypeand pages 1-2)

7.3 UBERON suggestions

  • Brain white matter (UBERON:0006102)
  • Corpus callosum (UBERON:0002335)
  • Cerebellum (UBERON:0002037)

8. Temporal development

  • Onset: variable; can be childhood-onset and progressive, but late onset has been documented (symptom onset at 19 and 41 years in siblings). (wu2019novelmutationsof pages 4-6, campopiano2020anovelpolr3a pages 1-2)
  • Progression: typically progressive motor and cognitive decline; examples include evolution to tetraparesis and severe cognitive regression in a late-onset sibling. (campopiano2020anovelpolr3a pages 1-2)

9. Inheritance and population

  • Inheritance: autosomal recessive / biallelic. (lynch2022clinicalandgenetic pages 42-46, wu2019novelmutationsof pages 4-6, macintosh2023biallelicpathogenicvariants pages 1-2)
  • Epidemiology: disease prevalence/incidence estimates were not available in the retrieved evidence set.
  • Sex ratio: not established in the retrieved evidence set.
  • Founder effects: not established for HLD7 specifically in the retrieved evidence set (though founder/recurrent variants are discussed in the broader POLR3-related spectrum). (wolf2014clinicalspectrumof pages 1-2)

10. Diagnostics

10.1 Clinical/imaging diagnosis

MRI is central for recognition of hypomyelinating leukodystrophies and for pattern recognition supporting POLR3-related leukodystrophy: - Classic MRI pattern described in a 105-case series: “hypomyelination with relative T2 hypointensity of the ventrolateral thalamus, optic radiation, globus pallidus, and dentate nucleus, cerebellar atrophy, and thinning of the corpus callosum.” (wolf2014clinicalspectrumof pages 1-2)

10.2 Genetic testing (real-world implementation)

  • Trio sequencing approaches are used in practice; one HLD7 report used trio medical exome sequencing to identify compound heterozygous POLR3A variants with co-segregation. (wu2019novelmutationsof pages 4-6)
  • In a trio-WES cohort study of hypomyelinating leukodystrophy, POLR3A variants were among the detected causes and splice disruption was functionally supported by minigene assay. (yan2021geneticanalysisof pages 4-6)

10.3 Differential diagnosis

The retrieved evidence does not provide a structured differential list, but HLD7 should be considered among other hypomyelinating leukodystrophies; broad diagnostic approaches emphasize integrating MRI pattern recognition with molecular testing. (torii2023molecularpathogenicmechanisms pages 1-2, wolf2014clinicalspectrumof pages 1-2)

11. Outcome / prognosis

Natural history, survival, and validated prognostic factors were not quantified in the retrieved evidence set. Available case reports demonstrate substantial variability, ranging from progressive childhood neurodegeneration to later-onset milder courses, and severe disability can develop. (campopiano2020anovelpolr3a pages 1-2)

12. Treatment

12.1 Current standard of care

No disease-modifying therapy for HLD7 was identified in the retrieved evidence set. Management is described as multidisciplinary and symptomatic, consistent with general leukodystrophy care practices. (ruan2024clinicalphenotypeand pages 12-13)

12.2 Emerging/experimental approaches (research stage)

A 2024 precision-medicine review describes efforts to build platforms for early detection and therapeutic development in leukodystrophies (including POLR3-related leukodystrophy), emphasizing single-cell omics and drug screening rather than established clinical interventions. (coulombe2024towardsatreatment pages 2-4)

12.3 Clinical trials

No interventional clinical trials specific to HLD7/POLR3A were identified in the clinical trial search results available in this run (trials retrieved were for other leukodystrophies such as metachromatic leukodystrophy). Therefore, HLD7-specific trial status cannot be asserted from the current evidence set.

12.4 MAXO term suggestions (supportive)

  • Genetic counseling (MAXO:0000074)
  • Physical therapy / rehabilitation therapy (MAXO:0000012)
  • Speech therapy (MAXO:0000126)
  • Symptomatic management (MAXO:0000159)

13. Prevention

Because HLD7 is autosomal recessive, prevention is primarily via carrier testing, reproductive counseling, and prenatal/preimplantation genetic testing where appropriate; disease-specific guidelines were not retrieved here, but the inheritance pattern is well established. (lynch2022clinicalandgenetic pages 42-46, wu2019novelmutationsof pages 4-6)

14. Other species / natural disease

No naturally occurring non-human disease analogs were identified in the retrieved evidence set.

15. Model organisms

The retrieved evidence set did not include detailed animal-model phenotype excerpts for HLD7-specific alleles; however, the literature acknowledges model limitations for some POLR3A alleles and the need for appropriate allele/model selection when studying POLR3-related disease biology. (ruan2024clinicalphenotypeand pages 13-13)

Recent developments (2023–2024) — highlighted points

1) Updated mechanistic synthesis (2023): A 2023 review explicitly lists HLD7 as OMIM 607694 with causal gene POLR3A, situating it within the expanding genetic landscape of hypomyelinating leukodystrophies enabled by next-generation sequencing. (torii2023molecularpathogenicmechanisms pages 1-2) 2) Human functional validation (2024): A 2024 family study reports POLR3A c.2300G>T (p.Cys767Phe) and provides functional evidence of impaired Pol III transcription with downstream reduction in myelin-related expression readouts (e.g., MBP). (ruan2024clinicalphenotypeand pages 1-2) 3) Precision-medicine strategy proposals (2024): A 2024 review proposes single-cell omics and systematic drug screening platforms to stratify leukodystrophy patients and develop rational therapies, explicitly including POLR3-related leukodystrophy within scope. (coulombe2024towardsatreatment pages 2-4)

Key statistics and data points (from retrieved primary literature)

  • 105 mutation-proven cases of 4H leukodystrophy caused by POLR3A/POLR3B were analyzed in a multinational cross-sectional study, with noted gene-dependent severity (“milder in patients with POLR3B than in patients with POLR3A mutations”). (wolf2014clinicalspectrumof pages 1-2)
  • A 3T MRI series reported 12 patients with mutations distributed across POLR3 genes (POLR3A n=8; POLR3B n=3; POLR1C n=1) and described additional imaging signs at higher field strength. (cayami20184hleukodystrophylessons pages 1-2)
  • A case-report literature summary stated: “There are 62 pathogenic variants associated with POLR3-related leukodystrophy,” and that “14 different mutations in the POLR3A gene have been reported” (note: case-report level compilation; may not reflect current database totals). (wu2019novelmutationsof pages 4-6)

Authoritative interpretation / expert perspective (evidence-backed)

The contemporary view is that HLD7 is best understood within the POLR3-related leukodystrophy spectrum, where diagnostic confidence comes from the combination of a recognizable MRI pattern and biallelic pathogenic variants, while clinical severity is heterogeneous and not fully explained by genotype alone—motivating current 2023–2024 emphasis on mechanistic studies (Pol III transcript dysregulation) and precision-medicine platforms to identify vulnerable cell types and candidate interventions. (torii2023molecularpathogenicmechanisms pages 1-2, wolf2014clinicalspectrumof pages 1-2, coulombe2024towardsatreatment pages 2-4, ruan2024clinicalphenotypeand pages 1-2)

Source URLs (most central)

  • Wolf et al., Neurology (2014-11), “Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations.” https://doi.org/10.1212/WNL.0000000000001002 (wolf2014clinicalspectrumof pages 1-2)
  • Cayami et al., Neuropediatrics (published online 2017-11-27; issue 2018-11), “4H Leukodystrophy: Lessons from 3T Imaging.” https://doi.org/10.1055/s-0037-1608780 (cayami20184hleukodystrophylessons pages 1-2)
  • Ruan et al., Scientific Reports (2024-04), “Clinical phenotype and genetic function analysis of a family with hypomyelinating leukodystrophy-7 caused by POLR3A mutation.” https://doi.org/10.1038/s41598-024-58452-6 (ruan2024clinicalphenotypeand pages 1-2)
  • Torii & Yamauchi, Neurology International (2023-09), “Molecular Pathogenic Mechanisms of Hypomyelinating Leukodystrophies (HLDs).” https://doi.org/10.3390/neurolint15030072 (torii2023molecularpathogenicmechanisms pages 1-2)
  • Coulombe et al., Biomolecules (2024-07), “Towards a Treatment for Leukodystrophy Using Cell-Based Interception and Precision Medicine.” https://doi.org/10.3390/biom14070857 (coulombe2024towardsatreatment pages 2-4)

References

  1. (torii2023molecularpathogenicmechanisms pages 1-2): Tomohiro Torii and Junji Yamauchi. Molecular pathogenic mechanisms of hypomyelinating leukodystrophies (hlds). Neurology International, 15:1155-1173, Sep 2023. URL: https://doi.org/10.3390/neurolint15030072, doi:10.3390/neurolint15030072. This article has 18 citations.

  2. (wolf2014clinicalspectrumof pages 1-2): Nicole I. Wolf, Adeline Vanderver, Rosalina M.L. van Spaendonk, Raphael Schiffmann, Bernard Brais, Marianna Bugiani, Erik Sistermans, Coriene Catsman-Berrevoets, Johan M. Kros, Pedro Soares Pinto, Daniela Pohl, Sandya Tirupathi, Petter Strømme, Ton de Grauw, Sébastien Fribourg, Michelle Demos, Amy Pizzino, Sakkubai Naidu, Kether Guerrero, Marjo S. van der Knaap, and Geneviève Bernard. Clinical spectrum of 4h leukodystrophy caused by polr3a and polr3b mutations. Neurology, 83:1898-1905, Nov 2014. URL: https://doi.org/10.1212/wnl.0000000000001002, doi:10.1212/wnl.0000000000001002. This article has 245 citations and is from a highest quality peer-reviewed journal.

  3. (macintosh2023biallelicpathogenicvariants pages 1-2): Julia Macintosh, Stefanie Perrier, Maxime Pinard, Luan T. Tran, Kether Guerrero, Chitra Prasad, Asuri N. Prasad, Tomi Pastinen, Isabelle Thiffault, Benoit Coulombe, and Geneviève Bernard. Biallelic pathogenic variants in polr3d alter trna transcription and cause a hypomyelinating leukodystrophy: a case report. Frontiers in Neurology, Oct 2023. URL: https://doi.org/10.3389/fneur.2023.1254140, doi:10.3389/fneur.2023.1254140. This article has 17 citations and is from a peer-reviewed journal.

  4. (ruan2024clinicalphenotypeand pages 1-2): Dan-dan Ruan, Xing-Lin Ruan, Ruolong Wang, Xin-fu Lin, Yan-ping Zhang, Bin Lin, Shi-jie Li, Min Wu, Qian Chen, Jian-Hui Zhang, Qiong Cheng, Yi-wu Zhang, Fan Lin, Jie-wei Luo, Zheng Zheng, and Yun-fei Li. Clinical phenotype and genetic function analysis of a family with hypomyelinating leukodystrophy-7 caused by polr3a mutation. Scientific Reports, Apr 2024. URL: https://doi.org/10.1038/s41598-024-58452-6, doi:10.1038/s41598-024-58452-6. This article has 5 citations and is from a peer-reviewed journal.

  5. (lynch2022clinicalandgenetic pages 42-46): David S. Lynch, Anderson Rodrigues Brandão de Paiva, Wei Zhang, E. Bugiardini, F. Freua, L. Tavares Lucato, Lúcia I Macedo-Souza, R. Lakshmanan, J. Kinsella, Á. Merwick, A. Rossor, N. Bajaj, B. Herron, P. Mcmonagle, P. Morrison, D. Hughes, A. Pittman, M. Laurá, M. Reilly, J. Warren, C. Mummery, J. Schott, M. Adams, Nick C Fox, E. Murphy, I. Davagnanam, F. Kok, J. Chataway, and H. Houlden. Clinical and genetic characterization of leukoencephalopathies in adults. Brain, 140:1204-1211, Mar 2022. URL: https://doi.org/10.1093/brain/awx045, doi:10.1093/brain/awx045. This article has 85 citations and is from a highest quality peer-reviewed journal.

  6. (cayami20184hleukodystrophylessons pages 1-2): Ferdy Cayami, Marianna Bugiani, Petra Pouwels, Geneviève Bernard, Marjo van der Knaap, and Nicole Wolf. 4h leukodystrophy: lessons from 3t imaging. Neuropediatrics, 49:112-117, Nov 2018. URL: https://doi.org/10.1055/s-0037-1608780, doi:10.1055/s-0037-1608780. This article has 21 citations and is from a peer-reviewed journal.

  7. (yan2021geneticanalysisof pages 4-6): Huifang Yan, Haoran Ji, Thomas Kubisiak, Ye Wu, Jiangxi Xiao, Qiang Gu, Yanling Yang, Han Xie, Taoyun Ji, Kai Gao, Dongxiao Li, Hui Xiong, Zhen Shi, Ming Li, Yuehua Zhang, Ruoyu Duan, Xinhua Bao, Yuwu Jiang, Margit Burmeister, and Jingmin Wang. Genetic analysis of 20 patients with hypomyelinating leukodystrophy by trio-based whole-exome sequencing. Journal of Human Genetics, 66:761-768, Feb 2021. URL: https://doi.org/10.1038/s10038-020-00896-5, doi:10.1038/s10038-020-00896-5. This article has 54 citations and is from a peer-reviewed journal.

  8. (wu2019novelmutationsof pages 1-4): Shuiyan Wu, Zhenjiang Bai, Xingqiang Dong, Daoping Yang, Hongmei Chen, Jun Hua, Libing Zhou, and Haitao Lv. Novel mutations of polr3a gene caused hypomyelinating leukodystrophy type 7 (hld7) in a chinese family: a case report. ArXiv, Jun 2019. URL: https://doi.org/10.21203/rs.2.10640/v1, doi:10.21203/rs.2.10640/v1. This article has 0 citations.

  9. (campopiano2020anovelpolr3a pages 1-2): Rosa Campopiano, Rosangela Ferese, Stefania Zampatti, Emiliano Giardina, Francesca Biagioni, Claudio Colonnese, Diego Centonze, Marianna Storto, Fabio Buttari, Edoardo Fraviga, Vania Broccoli, Mirco Fanelli, Francesco Fornai, and Stefano Gambardella. A novel polr3a genotype leads to leukodystrophy type-7 in two siblings with unusually late age of onset. BMC Neurology, Jun 2020. URL: https://doi.org/10.1186/s12883-020-01835-9, doi:10.1186/s12883-020-01835-9. This article has 13 citations and is from a peer-reviewed journal.

  10. (ruan2024clinicalphenotypeand pages 12-13): Dan-dan Ruan, Xing-Lin Ruan, Ruolong Wang, Xin-fu Lin, Yan-ping Zhang, Bin Lin, Shi-jie Li, Min Wu, Qian Chen, Jian-Hui Zhang, Qiong Cheng, Yi-wu Zhang, Fan Lin, Jie-wei Luo, Zheng Zheng, and Yun-fei Li. Clinical phenotype and genetic function analysis of a family with hypomyelinating leukodystrophy-7 caused by polr3a mutation. Scientific Reports, Apr 2024. URL: https://doi.org/10.1038/s41598-024-58452-6, doi:10.1038/s41598-024-58452-6. This article has 5 citations and is from a peer-reviewed journal.

  11. (wu2019novelmutationsof pages 4-6): Shuiyan Wu, Zhenjiang Bai, Xingqiang Dong, Daoping Yang, Hongmei Chen, Jun Hua, Libing Zhou, and Haitao Lv. Novel mutations of polr3a gene caused hypomyelinating leukodystrophy type 7 (hld7) in a chinese family: a case report. ArXiv, Jun 2019. URL: https://doi.org/10.21203/rs.2.10640/v1, doi:10.21203/rs.2.10640/v1. This article has 0 citations.

  12. (musumeci2022identificationofa pages 3-5): Antonino Musumeci, Francesco Calì, Carmela Scuderi, Mirella Vinci, Girolamo Aurelio Vitello, Sebastiano Antonino Musumeci, Valeria Chiavetta, Concetta Federico, Greta Amore, Salvatore Saccone, Gabriella Di Rosa, and Antonio Gennaro Nicotera. Identification of a novel missense mutation of polr3a gene in a cohort of sicilian patients with leukodystrophy. Biomedicines, 10:2276, Sep 2022. URL: https://doi.org/10.3390/biomedicines10092276, doi:10.3390/biomedicines10092276. This article has 16 citations.

  13. (coulombe2024towardsatreatment pages 8-9): Benoit Coulombe, Alexandra Chapleau, Julia Macintosh, Thomas M. Durcan, Christian Poitras, Yena A. Moursli, Denis Faubert, Maxime Pinard, and Geneviève Bernard. Towards a treatment for leukodystrophy using cell-based interception and precision medicine. Biomolecules, 14:857, Jul 2024. URL: https://doi.org/10.3390/biom14070857, doi:10.3390/biom14070857. This article has 1 citations.

  14. (coulombe2024towardsatreatment pages 2-4): Benoit Coulombe, Alexandra Chapleau, Julia Macintosh, Thomas M. Durcan, Christian Poitras, Yena A. Moursli, Denis Faubert, Maxime Pinard, and Geneviève Bernard. Towards a treatment for leukodystrophy using cell-based interception and precision medicine. Biomolecules, 14:857, Jul 2024. URL: https://doi.org/10.3390/biom14070857, doi:10.3390/biom14070857. This article has 1 citations.

  15. (coulombe2024towardsatreatment pages 4-5): Benoit Coulombe, Alexandra Chapleau, Julia Macintosh, Thomas M. Durcan, Christian Poitras, Yena A. Moursli, Denis Faubert, Maxime Pinard, and Geneviève Bernard. Towards a treatment for leukodystrophy using cell-based interception and precision medicine. Biomolecules, 14:857, Jul 2024. URL: https://doi.org/10.3390/biom14070857, doi:10.3390/biom14070857. This article has 1 citations.

  16. (ruan2024clinicalphenotypeand pages 13-13): Dan-dan Ruan, Xing-Lin Ruan, Ruolong Wang, Xin-fu Lin, Yan-ping Zhang, Bin Lin, Shi-jie Li, Min Wu, Qian Chen, Jian-Hui Zhang, Qiong Cheng, Yi-wu Zhang, Fan Lin, Jie-wei Luo, Zheng Zheng, and Yun-fei Li. Clinical phenotype and genetic function analysis of a family with hypomyelinating leukodystrophy-7 caused by polr3a mutation. Scientific Reports, Apr 2024. URL: https://doi.org/10.1038/s41598-024-58452-6, doi:10.1038/s41598-024-58452-6. This article has 5 citations and is from a peer-reviewed journal.

Artifacts